Anderson Kenneth Carl 4

What Happened
Kenneth Carl Anderson (listed as Anderson Kenneth Carl), a director of C4 Therapeutics, was granted a derivative award covering 62,000 shares on 2026-06-24. The filing lists the acquisition price as $0.00 and a total reported value of $0. This is a grant/award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Form 4 filed 2026-06-26 (filed two days after the transaction, which generally meets Section 16 timing requirements).
• Instrument: Derivative award covering 62,000 shares; reported price $0.00; aggregate reported value $0.
• Vesting/exercise: Per footnote, the option/award "shall vest and become exercisable in full" upon the earlier of (i) June 24, 2027 or (ii) the issuer’s next annual meeting, subject to continued service as a board member.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing type: Grant/Award (code A) — treated as a derivative grant rather than an immediate purchase of common stock.

Context
This was a compensation-related derivative grant to a director. Such awards typically vest over time or upon meeting service conditions; they do not necessarily reflect an immediate cash outlay or sale. Because the award vests/becomes exercisable only upon the stated future events, it conveys potential future ownership if vesting conditions are met, but does not represent an immediate market purchase or sale.